Seattle Genetics Inc. (SGEN) ADCETRIS Gets FDA Approval

Seattle Genetics Incorporated - symbol SGEN - reported that the U.S. FDA has granted accelerated approval of ADCETRIS. ADCETRIS is the first approved by the FDA for Hodgkin lymphoma in more than 30 years, and provides a new therapeutic alternative for Hodgkin lymphoma and systemic anaplastic large cell lymphoma in these settings.